Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes

被引：11

作者：

Tamburini, J. ^{[1
]}

Elie, C. ^{[2
]}

Park, S. ^{[1
]}

Beyne-Rauzy, O. ^{[3
]}

Gardembas, M. ^{[4
]}

Berthou, C. ^{[5
]}

Mahe, B. ^{[6
]}

Sanhes, L. ^{[7
]}

Stamatoullas, A. ^{[8
]}

Vey, N. ^{[9
]}

Aouba, A.

Slama, B. ^{[10
]}

Quesnel, B. ^{[11
]}

Vekhoff, A. ^{[13
]}

Sotto, J. J. ^{[12
]}

Vassilief, D. ^{[1
]}

Al-Nawakil, C. ^{[1
]}

Fenaux, P. ^{[14
]}

Dreyfus, F. ^{[1
]}

Bouscary, D. ^{[1
]}

机构：

[1] Hop Cochin, Dept Haematol, Paris, France

[2] Univ Paris 05, Dept Biostat, F-75270 Paris 06, France

[3] Hop Purpan, Dept Hematol Odile, Toulouse, France

[4] Ctr Hosp Angers, Dept Hematol Martine, Angers, France

[5] Hop Brest, Dept Hematol Christian, Brest, France

[6] Ctr Hosp Nantes, Dept Hematol, Nantes, France

[7] Ctr Hosp Perpignan, Dept Hematol, Perpignan, France

[8] Ctr Hosp Rouen, Dept Hematol Aspasia, Rouen, France

[9] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France

[10] Ctr Hosp Avignon, Dept Hematol, Avignon, France

[11] Ctr Hosp Lille, Dept Hematol, Lille, France

[12] Ctr Hosp Grenoble, Dept Hematol, Grenoble, France

[13] Hop Hotel Dieu, Dept Hematol, F-75181 Paris, France

[14] Hop Avicenne, Dept Hematol, Bobigny, France

来源：

LEUKEMIA RESEARCH | 2009年 / 33卷 / 04期

关键词：

INTERNATIONAL WORKING GROUP; RESPONSE CRITERIA; ANEMIA; PROPOSAL;

D O I：

10.1016/j.leukres.2008.06.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：547 / 550

页数：4

共 50 条

[1] Treatment of low-risk myelodysplastic syndromes
Santini, Valeria
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 462 - 469
[2] rHuEpo treatment in low-risk myelodysplastic syndromes
Grossi, A
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) : 574 - 574
[3] Supportive therapy for low-risk myelodysplastic syndromes
Gay, Julie
HEMATOLOGIE, 2008, 14 (03): : 178 - 184
[4] Erythropoietin for the anemia of low-risk myelodysplastic syndromes
Fenaux, P
Ades, L
BLOOD, 2005, 106 (03) : 768 - 769
[5] Low-risk myelodysplastic syndromes and iron overload
Fenaux, Pierre
HEMATOLOGIE, 2006, 12 : 9 - 9
[6] Amifostine in the treatment of low-risk myelodysplastic syndromes
Grossi, A
Fabbri, A
Santini, V
Leoni, F
Nozzoli, C
Longo, G
Pagliai, G
Ciolli, S
Ferrini, PR
HAEMATOLOGICA, 2000, 85 (04) : 367 - 371
[7] High-dose rHuEPO for the treatment of patients with low-risk myelodysplastic syndromes
Latagliata, R.
Oliva, E.
Volpicelli, P.
Napoleone, L.
Carmosino, I.
Breccia, M.
Stefanizzi, C.
Vincelli, I.
Alati, C.
Vozella, F.
Nobile, F.
Alimena, G.
LEUKEMIA RESEARCH, 2009, 33 : S121 - S121
[8] Current treatment strategies in low-risk myelodysplastic syndromes
Giagounidis, Aristoteles A. N.
Germing, Ulrich
Aul, Carlo
CANCER TREATMENT REVIEWS, 2007, 33 : S19 - S24
[9] Hepcidin and Erythroferrone in the Anemia of Low-Risk Myelodysplastic Syndromes
Oarbeascoa, Gillen
Redondo, Sara
Jose Moran-Jimenez, Maria
Domingo, Amalia
Munoz-Linares, Cristina
Isabel Moreno-Carralero, Maria
Maria Bellon, Jose
del Campo Rincon, Juan Francisco
Luis Diez-Martin, Jose
Font, Patricia
BLOOD, 2018, 132
[10] BURDEN OF DISEASE IN LOW-RISK MYELODYSPLASTIC SYNDROMES IN SPAIN
Valcarcel, D.
Montoro, M. J.
Tormo, M.
Bargay, J.
Moreno, E.
Aceituno, S.
Bellmunt, A.
Soler, M.
Rafel, M.
Villarrubia, R.
VALUE IN HEALTH, 2022, 25 (12) : S155 - S156

← 1 2 3 4 5 →